25,427 results match your criteria Journal of the American College of Cardiology[Journal]


Correction.

Authors:

J Am Coll Cardiol 2019 Apr;73(15):2010

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.03.458DOI Listing

Translating Cardioprotection for Patient Benefit: The EU-CARDIOPROTECTION COST Action.

J Am Coll Cardiol 2019 Apr;73(15):2001-2003

Institute for Pathophysiology, West German Heart and Vascular Centre, University of Essen Medical School, Essen, Germany. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07351097193395
Publisher Site
http://dx.doi.org/10.1016/j.jacc.2019.03.020DOI Listing
April 2019
1 Read

Uncovering the Real Power and Value Behind ACC Membership.

Authors:
Richard J Kovacs

J Am Coll Cardiol 2019 Apr;73(15):1999-2000

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.03.460DOI Listing

Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week.

J Am Coll Cardiol 2019 Apr;73(15):1978-1986

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:

Hypertrophic cardiomyopathy (HCM) has been considered a heterogeneous cardiac disease ascribed solely to single sarcomere gene mutations. However, limitations of this hypothesis suggest that sarcomere mutations alone do not adequately explain all HCM clinical and pathobiological features. Disease-causing sarcomere mutations are absent in ∼70% of patients with established disease, and sarcomere gene carriers can live to advanced ages without developing HCM. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07351097193370
Publisher Site
http://dx.doi.org/10.1016/j.jacc.2019.01.061DOI Listing
April 2019
2 Reads

Left Atrial Structure and Function, and Left Ventricular Diastolic Dysfunction: JACC State-of-the-Art Review.

J Am Coll Cardiol 2019 Apr;73(15):1961-1977

University of Milano-Bicocca, Milan, Italy; IRCCS, Istituto Auxologico Italiano, S. Luca Hospital, Milan, Italy.

Defining left atrial (LA) function has recently emerged as a powerful parameter, particularly in evaluation of left ventricular (LV) diastolic dysfunction (LVDD) and heart failure with preserved ejection fraction. Echocardiographic assessment of LVDD by echocardiography remains a challenging task; recent recommendations provide a simpler approach than previous. However, the shortcomings of the proposed approach (including transmitral flow, tissue velocity, maximum left atrial volume [LAV], and estimated pulmonary artery systolic pressure), lead to the presence and severity of LVDD remaining undetermined in a significant proportion of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.01.059DOI Listing

Vascular Ehlers-Danlos Syndrome Management: The Paris Way, A Step Forward on a Long Road.

J Am Coll Cardiol 2019 Apr;73(15):1958-1960

Department of Cardiology, Ghent University Hospital, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.02.025DOI Listing

Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study.

J Am Coll Cardiol 2019 Apr;73(15):1948-1957

AP-HP, Hôpital Européen Georges Pompidou, Département de Génétique, Centre de Référence des Maladies Vasculaires Rares, Paris, France; INSERM, U 970, Paris Centre de Recherche Cardiovasculaire-PARCC, Paris, France; Université Paris Sorbonne Cité, Faculté de Médecine Paris Descartes, Paris, France. Electronic address:

Background: Vascular Ehlers-Danlos syndrome (vEDS) is a rare genetic connective tissue disorder secondary to pathogenic variants within the COL3A1 gene, resulting in exceptional arterial and organ fragility and premature death. The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality.

Objectives: The authors herein describe the outcomes of a large cohort of vEDS patients followed ≤17 years in a single national referral center. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07351097193369
Publisher Site
http://dx.doi.org/10.1016/j.jacc.2019.01.058DOI Listing
April 2019
1 Read

SGLT2 Inhibition: Changing What Fuels the Heart.

Authors:
Michael Lehrke

J Am Coll Cardiol 2019 Apr;73(15):1945-1947

Department of Internal Medicine I, University Hospital RWTH Aachen, Aachen, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.02.023DOI Listing

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.

J Am Coll Cardiol 2019 Apr;73(15):1931-1944

AtheroThrombosis Research Unit, Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:

Background: Empagliflozin cardiac benefits in the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial cannot be explained exclusively by its antihyperglycemic activity.

Objectives: The hypothesis was that empagliflozin's cardiac benefits are mediated by switching myocardial fuel metabolism away from glucose toward ketone bodies (KB), which improves myocardial energy production.

Methods: Heart failure was induced in nondiabetic pigs (n = 14) by 2-h balloon occlusion of the proximal left anterior descending artery. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07351097193368
Publisher Site
http://dx.doi.org/10.1016/j.jacc.2019.01.056DOI Listing
April 2019
9 Reads

The Guardian Will Alert You Soon.

J Am Coll Cardiol 2019 Apr;73(15):1928-1930

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07351097193060
Publisher Site
http://dx.doi.org/10.1016/j.jacc.2019.01.054DOI Listing
April 2019
1 Read

Application of Transcatheter Repair to Tricuspid Regurgitation: Still Looking Through a Dark Glass.

Authors:
Jeffrey S Borer

J Am Coll Cardiol 2019 Apr;73(15):1916-1918

College of Medicine, School of Public Health, SUNY Downstate Medical Center, Brooklyn, New York; Weill Cornell Medicine, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.02.026DOI Listing

6-Month Outcomes of Tricuspid Valve Reconstruction for Patients With Severe Tricuspid Regurgitation.

J Am Coll Cardiol 2019 Apr;73(15):1905-1915

Department of Cardiovascular Surgery, University Hospital Zurich, Zurich, Switzerland.

Background: Severe tricuspid regurgitation (TR) is associated with high morbidity and mortality rates with limited treatment options.

Objectives: The authors report the 6-month safety and performance of a transcatheter tricuspid valve reconstruction system in the treatment of moderate to severe functional TR in 30 patients enrolled in the TRI-REPAIR (TrIcuspid Regurgitation RePAIr With CaRdioband Transcatheter System) study.

Methods: Between October 2016 and July 2017, 30 patients were enrolled in this single-arm, multicenter, prospective trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.01.062DOI Listing

Age, STEMI, and Cardiogenic Shock: Never Too Old for PCI?

J Am Coll Cardiol 2019 Apr;73(15):1901-1904

The Duke University Medical Center/Duke Clinical Research Institute, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2018.12.088DOI Listing

Percutaneous Coronary Intervention in Older Patients With ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock.

J Am Coll Cardiol 2019 Apr;73(15):1890-1900

Sinai Hospital of Baltimore, LifeBridge Health Cardiovascular Institute, Baltimore, Maryland; University of Michigan Health System, Ann Arbor, Michigan. Electronic address:

Background: Older adults ≥75 years of age carry an increased risk of mortality after ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock.

Objectives: The purpose of this study was to examine the use of percutaneous coronary intervention (PCI) in older adults with STEMI and shock and its influence on in-hospital mortality.

Methods: We used a large publicly available all-payer inpatient health care database sponsored by the Agency for Healthcare Research and Quality between 1999 and 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.01.055DOI Listing
April 2019
1 Read

Outcomes After Coronary Artery Bypass: Getting Better All the Time.

J Am Coll Cardiol 2019 Apr;73(15):1887-1889

Division of Cardiac Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.01.060DOI Listing

Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery for Left Main Disease.

J Am Coll Cardiol 2019 Apr;73(15):1877-1886

Department of Cardiology, Imperial College of London, London, United Kingdom. Electronic address:

Background: Although results of percutaneous coronary intervention (PCI) have been steadily improving, whether surgical outcomes have improved over time is not fully elucidated.

Objectives: This study sought to compare the current outcomes of patients undergoing coronary artery bypass grafting (CABG) with prior surgical results, in the context of randomized trials including the left main (LM) coronary artery stem.

Methods: The authors performed a propensity-matched analysis of patients randomized to CABG in the SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) (enrollment period 2005 to 2007) and EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) (enrollment period 2010 to 2014) trials. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07351097193369
Publisher Site
http://dx.doi.org/10.1016/j.jacc.2018.12.090DOI Listing
April 2019
1 Read
16.503 Impact Factor

Confusing Data Analysis.

Authors:
Angela A Stanton

J Am Coll Cardiol 2019 Apr;73(14):1872-1873

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2018.11.065DOI Listing

Type 2 Myocardial Infarction: JACC Review Topic of the Week.

J Am Coll Cardiol 2019 Apr;73(14):1846-1860

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address:

Acute myocardial infarction (MI) can occur from increased myocardial oxygen demand and/or reduced supply in the absence of acute atherothrombotic plaque disruption; a condition called type 2 myocardial infarction (T2MI). As with any MI subtype, there must be clinical evidence of myocardial ischemia to make the diagnosis. This condition is increasingly diagnosed due to the increasing sensitivity of cardiac troponin assays and is associated with adverse short-term and long-term prognoses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.02.018DOI Listing
April 2019
1 Read

Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review.

J Am Coll Cardiol 2019 Apr;73(14):1827-1845

Depression and Anxiety Center for Discovery and Treatment, Department of Psychiatry, and Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:

Depression is a common problem in patients with cardiovascular disease (CVD) and is associated with increased mortality, excess disability, greater health care expenditures, and reduced quality of life. Depression is present in 1 of 5 patients with coronary artery disease, peripheral artery disease, and heart failure. Depression complicates the optimal management of CVD by worsening cardiovascular risk factors and decreasing adherence to healthy lifestyles and evidence-based medical therapies. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07351097193051
Publisher Site
http://dx.doi.org/10.1016/j.jacc.2019.01.041DOI Listing
April 2019
2 Reads

Modulating Adaptive Immunity in Vascular Disease: CD4 to the Fore.

J Am Coll Cardiol 2019 Apr;73(14):1824-1826

Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Vascular Research Division, Department of Pathology and the Center of Excellence in Vascular Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.01.050DOI Listing
April 2019
1 Read

CD28 Signaling Controls Metabolic Fitness of Pathogenic T Cells in Medium and Large Vessel Vasculitis.

J Am Coll Cardiol 2019 Apr;73(14):1811-1823

Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, California. Electronic address:

Background: In giant cell arteritis, vessel-wall infiltrating CD4 T cells and macrophages form tissue-destructive granulomatous infiltrates, and the artery responds with a maladaptive response to injury, leading to intramural neoangiogenesis, intimal hyperplasia, and luminal occlusion. Lesion-residing T cells receive local signals, which represent potential therapeutic targets.

Objectives: The authors examined how CD28 signaling affects vasculitis induction and maintenance, and which pathogenic processes rely on CD28-mediated T-cell activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.01.049DOI Listing
April 2019
1 Read

Unfolding the Roles of Mitochondria as Therapeutic Targets for Heart Disease.

J Am Coll Cardiol 2019 Apr;73(14):1807-1810

San Diego State University Heart Institute and the Department of Biology, San Diego State University, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2018.12.089DOI Listing

Cardioprotective Effect of the Mitochondrial Unfolded Protein Response During Chronic Pressure Overload.

J Am Coll Cardiol 2019 Apr;73(14):1795-1806

School of Cardiovascular Medicine & Sciences, King's College London British Heart Foundation Centre, London, United Kingdom. Electronic address:

Background: The mitochondrial unfolded protein response (UPR) is activated when misfolded proteins accumulate within mitochondria and leads to increased expression of mitochondrial chaperones and proteases to maintain protein quality and mitochondrial function. Cardiac mitochondria are essential for contractile function and regulation of cell viability, while mitochondrial dysfunction characterizes heart failure. The role of the UPR in the heart is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2018.12.087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456800PMC
April 2019
1 Read

The Changing Face of Cardiogenic Shock: A Challenge in Cardiac Critical Care.

Authors:
David A Morrow

J Am Coll Cardiol 2019 Apr;73(14):1792-1794

Samuel A. Levine Cardiac Intensive Care Unit and TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.02.022DOI Listing
April 2019
3 Reads

Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock.

J Am Coll Cardiol 2019 Apr;73(14):1781-1791

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Background: There are limited data on acute noncardiac multiorgan failure in cardiogenic shock complicating acute myocardial infarction (AMI-CS).

Objectives: The authors sought to evaluate the 15-year national trends, resource utilization, and outcomes of single and multiple noncardiac organ failures in AMI-CS.

Methods: This was a retrospective cohort study of AMI-CS using the National Inpatient Sample database from 2000 to 2014. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07351097193059
Publisher Site
http://dx.doi.org/10.1016/j.jacc.2019.01.053DOI Listing
April 2019
5 Reads
16.503 Impact Factor

RAAS Inhibition to Prevent GI Bleeding: Another Reason to Do the Right Thing.

J Am Coll Cardiol 2019 Apr;73(14):1779-1780

Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.01.052DOI Listing
April 2019
5 Reads

Effect of Angiotensin II Inhibitors on Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices.

J Am Coll Cardiol 2019 Apr;73(14):1769-1778

Department of Pharmacy Services, Medical University of South Carolina, Charleston, South Carolina.

Background: Angiotensin II receptor activation may result in angiogenesis, and ultimately arteriovenous malformations (AVM), through transforming growth factor (TGF)-β and angiopoietin-2 pathway activation.

Objectives: The goal of this study was to determine whether angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) were associated with lower risk of major gastrointestinal bleeds (GIB) and AVM-related GIBs in continuous-flow left ventricular assist device (CF-LVAD) patients.

Methods: The authors reviewed HeartMate II CF-LVAD recipients between January 2009 and July 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.01.051DOI Listing
April 2019
1 Read

Brugada Syndrome in the Young and in the Adult: A Tale of 2 Diseases?

J Am Coll Cardiol 2019 Apr;73(14):1766-1768

Cardiovascular Department, San Donato Hospital, Arezzo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.01.047DOI Listing
April 2019
1 Read

Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome.

J Am Coll Cardiol 2019 Apr;73(14):1756-1765

Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address:

Background: Information on young patients with Brugada syndrome (BrS) and arrhythmic events (AEs) is limited.

Objectives: The purpose of this study was to describe their characteristics and management as well as risk factors for AE recurrence.

Methods: A total of 57 patients (age ≤20 years), all with BrS and AEs, were divided into pediatric (age ≤12 years; n = 26) and adolescents (age 13 to 20 years; n = 31). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07351097193059
Publisher Site
http://dx.doi.org/10.1016/j.jacc.2019.01.048DOI Listing
April 2019
2 Reads